2020 ACC专家共识：降低2型糖尿病患者心血管风险的新型疗法决策路径

2020-08-05 美国心脏病学会 J Am Coll Cardiol.August 2020.

2020年8月，美国心脏病学会(ACC)发布了降低2型糖尿病患者心血管风险的新型疗法决策路径共识，本文是对2018年版专家共识决策路径的更新，并继续提供简明的降低T2D患者的CV风险的具体药物使用指导

中文标题：

英文标题：

2020 Expert Consensus Decision Pathway on Novel Therapies for Cardiovascular Risk Reduction in Patients With Type 2 Diabetes A Report of the American College of Cardiology Solution Set Oversight Committee

发布机构：

美国心脏病学会

发布日期：

2020-08-05

简要介绍：

2020年8月，美国心脏病学会(ACC)发布了降低2型糖尿病患者心血管风险的新型疗法决策路径共识，本文是对2018年版专家共识决策路径的更新，并继续提供简明的降低T2D患者的CV风险的具体药物使用指导。

相关资料下载：

GetToolGuiderByIdResponse(projectId=1, id=1f5b41c001951857, title=2020 ACC专家共识：降低2型糖尿病患者心血管风险的新型疗法决策路径, enTitle=2020 Expert Consensus Decision Pathway on Novel Therapies for Cardiovascular Risk Reduction in Patients With Type 2 Diabetes A Report of the American College of Cardiology Solution Set Oversight Committee, guiderFrom=J Am Coll Cardiol.August 2020., authorId=0, author=, summary=2020年8月，美国心脏病学会(ACC)发布了降低2型糖尿病患者心血管风险的新型疗法决策路径共识，本文是对2018年版专家共识决策路径的更新，并继续提供简明的降低T2D患者的CV风险的具体药物使用指导, cover=https://img.medsci.cn/2020813/1597329804740_2020535.jpg, journalId=0, articlesId=null, associationId=849, associationName=美国心脏病学会, associationIntro=null, copyright=0, guiderPublishedTime=Wed Aug 05 00:00:00 CST 2020, originalUrl=, linkOutUrl=, content=<div class="one_info2" style="color: #373737;"> <div id="all_content"> <div class="editor_mirror editor_mirror_del"> <p>2020年8月，美国心脏病学会(ACC)发布了降低2型糖尿病患者心血管风险的新型疗法决策路径共识，本文是对2018年版专家共识决策路径的更新，并继续提供简明的降低T2D患者的CV风险的具体药物使用指导。</p> </div> </div> </div>, tagList=[TagDto(tagId=1567, tagName=心血管风险), TagDto(tagId=2052, tagName=2型糖尿病)], categoryList=[CategoryDto(categoryId=2, categoryName=心血管, tenant=100), CategoryDto(categoryId=6, categoryName=内分泌科, tenant=100), CategoryDto(categoryId=8, categoryName=糖尿病, tenant=100), CategoryDto(categoryId=85, categoryName=指南&解读, tenant=100), CategoryDto(categoryId=21100, categoryName=达仁堂循证e学界, tenant=100)], articleKeywordId=0, articleKeyword=, articleKeywordNum=6, guiderKeywordId=2052, guiderKeyword=2型糖尿病, guiderKeywordNum=6, haveAttachments=1, attachmentList=null, guiderType=0, guiderArea=共识, guiderLanguage=1, guiderRegion=1, opened=0, paymentType=, paymentAmount=10, recommend=0, recommendEndTime=null, sticky=0, stickyEndTime=null, allHits=5248, appHits=246, showAppHits=0, pcHits=782, showPcHits=5002, likes=8, shares=27, comments=21, approvalStatus=1, publishedTime=Thu Aug 13 23:27:22 CST 2020, publishedTimeString=2020-08-05, pcVisible=1, appVisible=1, editorId=2020535, editor=qiushida2, waterMark=0, formatted=0, memberCards=[], isPrivilege=0, deleted=0, version=4, createdBy=null, createdName=qiushida2, createdTime=Thu Aug 13 22:43:32 CST 2020, updatedBy=6459136, updatedName=玉在山, updatedTime=Sat Jan 06 04:46:14 CST 2024, courseDetails=[], otherVersionGuiders=[OtherVersionToolGuiderDto(projectId=1, id=395c71c002e973af, title=2020年美国心脏病学会《降低2型糖尿病患者心血管风险新型疗法的专家共识决策路径》解读:降糖更要护心, enTitle=, guiderPublishedTime=Thu Dec 03 00:00:00 CST 2020, createdTime=Sat Nov 12 11:14:45 CST 2022), OtherVersionToolGuiderDto(projectId=1, id=e06481c00229369e, title=《ACC 2020降低2型糖尿病患者心血管风险新疗法的专家共识》解读, enTitle=, guiderPublishedTime=Sat Nov 20 00:00:00 CST 2021, createdTime=Fri Dec 17 22:25:56 CST 2021)], isGuiderMember=false, ipAttribution=, attachmentFileNameList=[AttachmentFileName(sort=1, fileName=2020 ACC专家共识：降低2型糖尿病患者心血管风险的新型疗法决策路径.pdf)])

2020 ACC专家共识：降低2型糖尿病患者心血管风险的新型疗法决策路径.pdf

下载请点击：

其他版本

2020年美国心脏病学会《降低2型糖尿病患者心血管风险新型疗法的专家共识决策路径》解读:降糖更要护心

《ACC 2020降低2型糖尿病患者心血管风险新疗法的专家共识》解读

评论区 (14)

#插入话题

插入图片

[GetPortalCommentsPageByObjectIdResponse(id=913678, encodeId=51499136e891, content=不错不错不错不错, beContent=null, objectType=guider, channel=null, level=null, likeNumber=130, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=8a875419228, createdName=ms8000000175105281, createdTime=Mon Jan 04 19:10:51 CST 2021, time=2021-01-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=896604, encodeId=ce338966045e, content=学习, beContent=null, objectType=guider, channel=null, level=null, likeNumber=153, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=dd582277740, createdName=121bb8d4m13暂无昵称, createdTime=Tue Nov 03 14:36:03 CST 2020, time=2020-11-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=896567, encodeId=db9e89656ebe, content=不错！学习了, beContent=null, objectType=guider, channel=null, level=null, likeNumber=139, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=cb355252510, createdName=147e4706m08暂无昵称, createdTime=Tue Nov 03 12:14:25 CST 2020, time=2020-11-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=894129, encodeId=43568941290c, content=好！好！好, beContent=null, objectType=guider, channel=null, level=null, likeNumber=142, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=1d885409355, createdName=一支烟, createdTime=Sat Oct 24 13:53:20 CST 2020, time=2020-10-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=883832, encodeId=646688383246, content=学习了, beContent=null, objectType=guider, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=6d095409783, createdName=ms5000002046462755, createdTime=Wed Sep 09 11:43:37 CST 2020, time=2020-09-09, status=1, ipAttribution=)]
2021-01-04 ms8000000175105281

不错不错不错不错

130 0
[GetPortalCommentsPageByObjectIdResponse(id=913678, encodeId=51499136e891, content=不错不错不错不错, beContent=null, objectType=guider, channel=null, level=null, likeNumber=130, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=8a875419228, createdName=ms8000000175105281, createdTime=Mon Jan 04 19:10:51 CST 2021, time=2021-01-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=896604, encodeId=ce338966045e, content=学习, beContent=null, objectType=guider, channel=null, level=null, likeNumber=153, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=dd582277740, createdName=121bb8d4m13暂无昵称, createdTime=Tue Nov 03 14:36:03 CST 2020, time=2020-11-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=896567, encodeId=db9e89656ebe, content=不错！学习了, beContent=null, objectType=guider, channel=null, level=null, likeNumber=139, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=cb355252510, createdName=147e4706m08暂无昵称, createdTime=Tue Nov 03 12:14:25 CST 2020, time=2020-11-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=894129, encodeId=43568941290c, content=好！好！好, beContent=null, objectType=guider, channel=null, level=null, likeNumber=142, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=1d885409355, createdName=一支烟, createdTime=Sat Oct 24 13:53:20 CST 2020, time=2020-10-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=883832, encodeId=646688383246, content=学习了, beContent=null, objectType=guider, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=6d095409783, createdName=ms5000002046462755, createdTime=Wed Sep 09 11:43:37 CST 2020, time=2020-09-09, status=1, ipAttribution=)]
2020-11-03 121bb8d4m13暂无昵称

学习

153 0
[GetPortalCommentsPageByObjectIdResponse(id=913678, encodeId=51499136e891, content=不错不错不错不错, beContent=null, objectType=guider, channel=null, level=null, likeNumber=130, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=8a875419228, createdName=ms8000000175105281, createdTime=Mon Jan 04 19:10:51 CST 2021, time=2021-01-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=896604, encodeId=ce338966045e, content=学习, beContent=null, objectType=guider, channel=null, level=null, likeNumber=153, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=dd582277740, createdName=121bb8d4m13暂无昵称, createdTime=Tue Nov 03 14:36:03 CST 2020, time=2020-11-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=896567, encodeId=db9e89656ebe, content=不错！学习了, beContent=null, objectType=guider, channel=null, level=null, likeNumber=139, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=cb355252510, createdName=147e4706m08暂无昵称, createdTime=Tue Nov 03 12:14:25 CST 2020, time=2020-11-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=894129, encodeId=43568941290c, content=好！好！好, beContent=null, objectType=guider, channel=null, level=null, likeNumber=142, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=1d885409355, createdName=一支烟, createdTime=Sat Oct 24 13:53:20 CST 2020, time=2020-10-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=883832, encodeId=646688383246, content=学习了, beContent=null, objectType=guider, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=6d095409783, createdName=ms5000002046462755, createdTime=Wed Sep 09 11:43:37 CST 2020, time=2020-09-09, status=1, ipAttribution=)]
2020-11-03 147e4706m08暂无昵称

不错！学习了

139 0
[GetPortalCommentsPageByObjectIdResponse(id=913678, encodeId=51499136e891, content=不错不错不错不错, beContent=null, objectType=guider, channel=null, level=null, likeNumber=130, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=8a875419228, createdName=ms8000000175105281, createdTime=Mon Jan 04 19:10:51 CST 2021, time=2021-01-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=896604, encodeId=ce338966045e, content=学习, beContent=null, objectType=guider, channel=null, level=null, likeNumber=153, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=dd582277740, createdName=121bb8d4m13暂无昵称, createdTime=Tue Nov 03 14:36:03 CST 2020, time=2020-11-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=896567, encodeId=db9e89656ebe, content=不错！学习了, beContent=null, objectType=guider, channel=null, level=null, likeNumber=139, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=cb355252510, createdName=147e4706m08暂无昵称, createdTime=Tue Nov 03 12:14:25 CST 2020, time=2020-11-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=894129, encodeId=43568941290c, content=好！好！好, beContent=null, objectType=guider, channel=null, level=null, likeNumber=142, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=1d885409355, createdName=一支烟, createdTime=Sat Oct 24 13:53:20 CST 2020, time=2020-10-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=883832, encodeId=646688383246, content=学习了, beContent=null, objectType=guider, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=6d095409783, createdName=ms5000002046462755, createdTime=Wed Sep 09 11:43:37 CST 2020, time=2020-09-09, status=1, ipAttribution=)]
2020-10-24 一支烟

好！好！好

142 0
[GetPortalCommentsPageByObjectIdResponse(id=913678, encodeId=51499136e891, content=不错不错不错不错, beContent=null, objectType=guider, channel=null, level=null, likeNumber=130, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=8a875419228, createdName=ms8000000175105281, createdTime=Mon Jan 04 19:10:51 CST 2021, time=2021-01-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=896604, encodeId=ce338966045e, content=学习, beContent=null, objectType=guider, channel=null, level=null, likeNumber=153, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=dd582277740, createdName=121bb8d4m13暂无昵称, createdTime=Tue Nov 03 14:36:03 CST 2020, time=2020-11-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=896567, encodeId=db9e89656ebe, content=不错！学习了, beContent=null, objectType=guider, channel=null, level=null, likeNumber=139, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=cb355252510, createdName=147e4706m08暂无昵称, createdTime=Tue Nov 03 12:14:25 CST 2020, time=2020-11-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=894129, encodeId=43568941290c, content=好！好！好, beContent=null, objectType=guider, channel=null, level=null, likeNumber=142, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=1d885409355, createdName=一支烟, createdTime=Sat Oct 24 13:53:20 CST 2020, time=2020-10-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=883832, encodeId=646688383246, content=学习了, beContent=null, objectType=guider, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=6d095409783, createdName=ms5000002046462755, createdTime=Wed Sep 09 11:43:37 CST 2020, time=2020-09-09, status=1, ipAttribution=)]
2020-09-09 ms5000002046462755

学习了

0 0

内科

外科

专科科室

热点

按科室浏览

临床工具

科研工具

其他工具

科研数智化

真实世界研究解决方案

数字化学术传播解决方案

其它

心血管指南

2020 ACC专家共识：降低2型糖尿病患者心血管风险的新型疗法决策路径

2020年美国心脏病学会《降低2型糖尿病患者心血管风险新型疗法的专家共识决策路径》解读:降糖更要护心

《ACC 2020降低2型糖尿病患者心血管风险新疗法的专家共识》解读

相关指南

拓展阅读

科室

工具

服务